The more scientists explore so-called "junk" DNA, the less the label seems to fit.
Only an estimated two percent of the human genome encodes for functional proteins that carry out normal biological processes. The remaining approximately 98 percent--the "junk DNA"--has for many years been considered a useless artifact. Some junk DNA has been shown to be transcribed into RNA molecules that support cellular functions, including transfer RNAs (tRNAS) and microRNAs (miRNAs), while the remaining noncoding RNA has continued to be considered nonfunctional "junk" RNA.
Previous work by researchers at the University of California San Diego in Assistant Professor Shannon Lauberth's lab uncovered several thousand enhancer RNAs (eRNAs) that are robustly produced in colon cancer cells in response to chronic immune signaling. eRNAs are a recently identified class of noncoding RNAs and their identification has begged the interesting question of whether they are functional in the cell. Now, members of the Lauberth team have revealed that eRNAs play a significant role in cancer dissemination.
Publishing their results in Nature Structural and Molecular Biology, UC San Diego graduate student Homa Rahnamoun, Lauberth and their colleagues found that eRNAs have a direct role in the activation of genes that are important for tumor development. This eRNA role is facilitated by the ability of the eRNAs to directly interact with BRD4, a protein known as a cancer disseminator. BRD4 has been recognized as a promising target in cancer and several small molecules developed to act against BRD4 are under active clinical investigations.
"Our findings reveal that eRNAs are key regulators of cancer by acting to reinforce BRD4 binding and keep it anchored on DNA, which keeps the tumor-promoting genes turned on at high levels," said Lauberth. "Interestingly, when we deplete several of these eRNAs, we can significantly reduce the expression of the tumor-promoting genes that the eRNAs and BRD4 are co-regulating."
Now that we see that eRNAs impact BRD4 function, we have to rethink the way that we therapeutically target BRD4, Lauberth says.
"Taken together, our findings are consistent with the emerging notion that eRNAs are functional molecules, rather than merely reflections of enhancer activation or simply transcriptional noise... So this is going to transform the way that we think about 'junk RNA' and the regulation of gene expression in the context of the human cell."
Future studies in the Lauberth lab will explore mechanisms of eRNA synthesis and function in gene regulation and the methods necessary to target eRNAs in order to halt their cancer-promoting mechanisms.